Finding high producing clones with monoclonality assurance in one day

In the discovery and development of novel biopharmaceuticals (antibodies) for therapeutic use, cell line development is an integral process in the biomanufacturing of therapeutic proteins. With the market demand for biotherapeutics increasing at a dramatic rate there is a pressing need to substantially shorten the development workflow. Cyto-Mine® utilizes established picodroplet technology to fast-track the generation of cell banks comprised of high-producing clones derived from single cells with monoclonality assurance. In this application note, Sphere Fluidics illustrates the process by which the Cyto-Mine® IgG secretion assay measures the productivity of hundreds of thousands of single cells encapsulated in highly consistent picoliter droplets or ‘test tubes’ while simultaneously providing verification of clonality.